Fromilid uno 斯洛伐克 - 斯洛伐克文 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

fromilid uno

krka, d.d., novo mesto, slovinsko - klaritromycín - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)

Biston 斯洛伐克 - 斯洛伐克文 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

biston

zentiva a.s., slovensko - karbamazepín - 21 - antiepileptica, anticonvulsiva

Dailiport 5 mg 斯洛伐克 - 斯洛伐克文 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

dailiport 5 mg

sandoz pharmaceuticals d.d., slovinsko - takrolimus - 59 - immunopraeparata

Dailiport 3 mg 斯洛伐克 - 斯洛伐克文 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

dailiport 3 mg

sandoz pharmaceuticals d.d., slovinsko - takrolimus - 59 - immunopraeparata

Dailiport 1 mg 斯洛伐克 - 斯洛伐克文 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

dailiport 1 mg

sandoz pharmaceuticals d.d., slovinsko - takrolimus - 59 - immunopraeparata

Dailiport 0,5 mg 斯洛伐克 - 斯洛伐克文 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

dailiport 0,5 mg

sandoz pharmaceuticals d.d., slovinsko - takrolimus - 59 - immunopraeparata

Lunsumio 欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

lunsumio

roche registration gmbh - mosunetuzumab - lymfóm, folikulárny - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Granisetron B. Braun 1 mg/ ml 斯洛伐克 - 斯洛伐克文 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

granisetron b. braun 1 mg/ ml

b.braun melsungen ag, nemecko - granisetrón - 20 - antiemetica, antivertiginosa

Kymriah 欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

kymriah

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - iné antineoplastické látky - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.